Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
13°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Celldex Therapeutics
(NQ:
CLDX
)
27.02
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Celldex Therapeutics
< Previous
1
2
3
4
5
6
Next >
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
November 20, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock
November 20, 2024
Via
Benzinga
Celldex Therapeutics to Present at Upcoming Investor Conferences
November 11, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Analyst Expectations For Celldex Therapeutics's Future
October 28, 2024
Via
Benzinga
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
October 26, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics
September 25, 2024
Via
Benzinga
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
October 25, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
September 27, 2024
Via
Benzinga
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
September 25, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
September 16, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
The Analyst Verdict: Celldex Therapeutics In The Eyes Of 7 Experts
September 09, 2024
Via
Benzinga
Celldex Therapeutics to Present at Upcoming Investor Conferences
September 12, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
7 Analysts Have This To Say About Celldex Therapeutics
August 12, 2024
Via
Benzinga
CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 09, 2024
CLDX stock results show that Celldex Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 08, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Lattice Semiconductor Posts Weak Q2 Results, Joins Symbotic, Woodward And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
July 30, 2024
Via
Benzinga
Analyst Expectations For Celldex Therapeutics's Future
July 16, 2024
Via
Benzinga
Analyst Expectations For Celldex Therapeutics's Future
June 03, 2024
Via
Benzinga
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 30, 2024
Via
Benzinga
Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
July 30, 2024
Via
Benzinga
Unveiling 4 Analyst Insights On Celldex Therapeutics
May 07, 2024
Via
Benzinga
Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
July 29, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
July 28, 2024
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%
Via
Benzinga
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
July 16, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics to Present at Jefferies Healthcare Conference
June 04, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
June 02, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
May 15, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 06, 2024
CLDX stock results show that Celldex Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 06, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
April 17, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
